Top Markets
Coin of the day
Medigen Biotechnology Corp. Medigen Biotechnology Corp.

Medigen Biotechnology Corp.

3176
Pozycja w akcjach #19056
Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated... Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural killer cells, and MAGICELL-GDT, a T-cell-based treatment. A significant pipeline asset for Medigen is OBP-301. This therapeutic has completed Phase I clinical trials for combination therapy in esophageal cancer in Japan. It is currently being evaluated in ongoing Phase I trials in Japan, combining it with immune checkpoint inhibitors (ICIs) for esophageal cancer, and has advanced to Phase II studies in the United States, investigating its use with ICIs for both esophageal and gastric cancer. Established in 1999, Medigen Biotechnology Corp. maintains its corporate headquarters in Taipei, Taiwan.
Cena akcji
$1.27
Kapitalizacja rynkowa
$176.31M
Zmiana (1 dzień)
5.57%
Zmiana (1 rok)
29.36%
Kraj
TW
Handel Medigen Biotechnology Corp. (3176)

Kategoria

Historia stopy dywidendy dla Medigen Biotechnology Corp. (3176)
Stopa dywidendy (TTM) dla Medigen Biotechnology Corp. (symbol akcji: 3176) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Medigen Biotechnology Corp. (3176) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji